Journal: Viruses

Article Title: Pemphigus and Bullous Pemphigoid Following COVID-19 Vaccination: A Systematic Review

doi: 10.3390/v16121896

Figure Lengend Snippet: Pemphigus and BP following COVID-19 vaccination. BP: bullous pemphigoid; PV: pemphigus vulgaris (PV); PF: pemphigus foliaceus.

Article Snippet: BP , 89, M , Pfizer/BioNTech First dose , 2 , New onset.

Techniques: Membrane

Journal: Vaccines

Article Title: Initial Mix-and-Match COVID-19 Vaccination Perceptions, Concerns, and Side Effects across Canadians

doi: 10.3390/vaccines10010093

Figure Lengend Snippet: Demographic characteristics of participants ( N = 1002).

Article Snippet: Thus, those who received the adenoviral vector vaccine first were more likely to switch to an mRNA dose later on when Pfizer-BioNTech and Moderna became more readily available, especially due to the safety concerns and risks of Oxford-AstraZeneca in younger adults (under 55) in Canada and other countries across the world [ , , ].

Techniques: Infection

Journal: Vaccines

Article Title: Initial Mix-and-Match COVID-19 Vaccination Perceptions, Concerns, and Side Effects across Canadians

doi: 10.3390/vaccines10010093

Figure Lengend Snippet: Total average amount of self-reported side effects after each vaccination by brand of vaccine ( N = 1002).

Article Snippet: Thus, those who received the adenoviral vector vaccine first were more likely to switch to an mRNA dose later on when Pfizer-BioNTech and Moderna became more readily available, especially due to the safety concerns and risks of Oxford-AstraZeneca in younger adults (under 55) in Canada and other countries across the world [ , , ].

Techniques:

Journal: Pediatric Blood & Cancer

Article Title: COVID‐19 vaccine (mRNA BNT162b2) and COVID‐19 infection‐induced thrombotic thrombocytopenic purpura in adolescents

doi: 10.1002/pbc.29681

Figure Lengend Snippet: Patient characteristics and summary of COVID‐19 vaccination or infection‐induced TTP course

Article Snippet: 2 , 15 , F , Arrhythmia of unknown etiology, previously on metoprolol , Pfizer‐BioNTech mRNA vaccine dose 1 , Not reported; SARS‐CoV‐2 Anti‐Spike IgM positive after vaccination , Fatigue, bruising , TPE x 4 days, methylprednisolone, rituximab, FFP infusion , Herpes zoster infection, weight gain , In remission.

Techniques: Infection

Journal: Viruses

Article Title: Pemphigus and Bullous Pemphigoid Following COVID-19 Vaccination: A Systematic Review

doi: 10.3390/v16121896

Figure Lengend Snippet: Pemphigus and BP following COVID-19 vaccination. BP: bullous pemphigoid; PV: pemphigus vulgaris (PV); PF: pemphigus foliaceus.

Article Snippet: Bardazzi et al. [ ] , 4 , BP , 76, F , Pfizer/BioNTech Third dose , 12 , New onset.

Techniques: Membrane

Journal: Cell Host & Microbe

Article Title: Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between doses

doi: 10.1016/j.chom.2021.12.004

Figure Lengend Snippet: Fc-effector function and neutralization activities in SARS-CoV-2 naive and previously-infected individuals before and after Pfizer/BioNTech mRNA vaccine (A) CEM.NKr parental cells were mixed at a 1:1 ratio with CEM.NKr-S cells and were used as target cells. PBMCs from uninfected donors were used as effector cells in a FACS-based ADCC assay. (B) Neutralizing activity was measured by incubating pseudoviruses bearing SARS-CoV-2 S glycoproteins with serial dilutions of plasma for 1 h at 37°C before infecting 293T-ACE2 cells. Neutralization half maximal inhibitory serum dilution (ID 50 ) values were determined using a normalized non-linear regression using GraphPad Prism software. Naive and PI donors with a long interval between the two doses are represented by red and black points, respectively, and PI donors who received just one dose by blue points. Left panels: Each curve represents the values obtained with the plasma of one donor at every time point. Mean of each group is represented by a bold line. The time of vaccine dose injections is indicated by black triangles. Right panels: Plasma samples were grouped in different time points (V0, V1, V2, V3, and V4). Undetectable measures are represented as white symbols, and limits of detection are plotted. Error bars indicate means ± SEM ( ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001; ∗∗∗∗ p < 0.0001; ns, non-significant). For naive donors, n = 26 at V0, V1, V2, and V3 and n = 22 at V4. For PI donors vaccinated with two doses, n = 15 at V0, V1, V2, and V3 and n = 12 at V4. For PI donors vaccinated with one dose, n = 12 at V0, V1, V2, and V3 and n = 7 at V4.

Article Snippet: We ( ) and others ( ; ; ; ) have reported that 3 weeks post first Pfizer/BioNTech dose, SARS-CoV-2 S-specific Abs with weak neutralizing properties are elicited.

Techniques: Neutralization, Infection, ADCC Assay, Activity Assay, Software

Journal: Cell Host & Microbe

Article Title: Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between doses

doi: 10.1016/j.chom.2021.12.004

Figure Lengend Snippet: Mesh correlations of humoral response parameters in SARS-CoV-2-naive and previously infected individuals before and after Pfizer/BioNTech mRNA vaccine. Edge bundling correlation plots where red and blue edges represent positive and negative correlations between connected parameters, respectively. Only significant correlations (p < 0.05, Spearman rank test) are displayed. Nodes are color-coded based on the grouping of parameters according to the legend. Node size corresponds to the degree of relatedness of correlations. Edge bundling plots are shown for correlation analyses using ten different datasets, i.e., SARS-CoV-2 naive (A) or PI (B) individuals at V0, V1, V2, V3, and V4, respectively.

Article Snippet: We ( ) and others ( ; ; ; ) have reported that 3 weeks post first Pfizer/BioNTech dose, SARS-CoV-2 S-specific Abs with weak neutralizing properties are elicited.

Techniques: Infection